BACKGROUND: To investigate immune reactions after reduced-intensity cord-blood transplantation (RI-CBT). MATERIALS AND METHODS: We reviewed medical records of 57 adult RI-CBT recipients. Preparative regimen comprised fludarabine, total-body irradiation, and either melphalan (n=51) or busulfan (n=6). Graft-versus-host disease (GvHD) prophylaxis was cyclosporine. PostRI-CBT immune reactions were classified according to time course: pre-engraftment immune reactions (PIR), engraftment syndrome (ES), and GvHD. RESULTS: Forty-five patients achieved engraftment at a median of day 19. PIR was characterized by high-grade fever and weight gain and developed on a median of day 9 in 35 of the 45 evaluable patients, including 3 who did not achieve engraftment. PIR subsided spontaneously in 12 patients, whereas corticosteroids were required in the other 23. ES and grade I to IV acute GvHD developed in 36 and 29 patients, respectively. GvHD could not be distinguished from preceding PIR or ES in 10 patients. Causes of the 32 nonrelapse mortalities included GvHD (n=5) and PIR (n=1). There were no significant differences in relapse and nonrelapse deaths between patients with PIR and those without it (18% vs. 5%, and 60% vs. 65%, respectively). CONCLUSIONS: Immune reactions after RI-CBT can be categorized into three distinct subtypes.
BACKGROUND: To investigate immune reactions after reduced-intensity cord-blood transplantation (RI-CBT). MATERIALS AND METHODS: We reviewed medical records of 57 adult RI-CBT recipients. Preparative regimen comprised fludarabine, total-body irradiation, and either melphalan (n=51) or busulfan (n=6). Graft-versus-host disease (GvHD) prophylaxis was cyclosporine. PostRI-CBT immune reactions were classified according to time course: pre-engraftment immune reactions (PIR), engraftment syndrome (ES), and GvHD. RESULTS: Forty-five patients achieved engraftment at a median of day 19. PIR was characterized by high-grade fever and weight gain and developed on a median of day 9 in 35 of the 45 evaluable patients, including 3 who did not achieve engraftment. PIR subsided spontaneously in 12 patients, whereas corticosteroids were required in the other 23. ES and grade I to IV acute GvHD developed in 36 and 29 patients, respectively. GvHD could not be distinguished from preceding PIR or ES in 10 patients. Causes of the 32 nonrelapse mortalities included GvHD (n=5) and PIR (n=1). There were no significant differences in relapse and nonrelapse deaths between patients with PIR and those without it (18% vs. 5%, and 60% vs. 65%, respectively). CONCLUSIONS: Immune reactions after RI-CBT can be categorized into three distinct subtypes.
Authors: V Camus; J-P Bouwyn; A Chamseddine; P Lenain; P Ahtoy; A Stamatoullas; H Lanic; E Lemasle; N Contentin; O Cassuto; S Leprêtre; S Dubois; H Tilly; F Jardin Journal: Bone Marrow Transplant Date: 2015-07-06 Impact factor: 5.483
Authors: M Ogata; K Oshima; T Ikebe; K Takano; H Kanamori; T Kondo; Y Ueda; T Mori; H Hashimoto; H Ogawa; T Eto; T Ueki; T Miyamoto; T Ichinohe; Y Atsuta; T Fukuda Journal: Bone Marrow Transplant Date: 2017-08-07 Impact factor: 5.483
Authors: J Kanda; L Kaynar; Y Kanda; V K Prasad; S H Parikh; L Lan; T Shen; D A Rizzieri; G D Long; K M Sullivan; C Gasparetto; J P Chute; A Morris; S Winkel; J McPherson; J Kurtzberg; N J Chao; M E Horwitz Journal: Bone Marrow Transplant Date: 2013-01-21 Impact factor: 5.483